Skip to Content

Editas Medicine Inc EDIT

Morningstar Rating
$10.06 −1.01 (9.12%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

EDIT is trading at a 51% discount.
Price
$10.99
Fair Value
$64.48
Uncertainty
Extreme
1-Star Price
$97.74
5-Star Price
$5.31
Economic Moat
Xcj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EDIT is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$11.07
Day Range
$10.0211.38
52-Week Range
$6.0811.91
Bid/Ask
$10.06 / $10.18
Market Cap
$821.64 Mil
Volume/Avg
3.9 Mil / 2.0 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
10.76
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
226

Comparables

Valuation

Metric
EDIT
NTLA
CRSP
Price/Earnings (Normalized)
Price/Book Value
2.592.903.73
Price/Sales
10.7680.2718.77
Price/Cash Flow
Price/Earnings
EDIT
NTLA
CRSP

Financial Strength

Metric
EDIT
NTLA
CRSP
Quick Ratio
5.278.2317.41
Current Ratio
5.398.6717.54
Interest Coverage
Quick Ratio
EDIT
NTLA
CRSP

Profitability

Metric
EDIT
NTLA
CRSP
Return on Assets (Normalized)
−26.43%−25.49%−3.61%
Return on Equity (Normalized)
−37.32%−30.88%−4.34%
Return on Invested Capital (Normalized)
−38.19%−31.84%−3.83%
Return on Assets
EDIT
NTLA
CRSP
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRDglv$541.4 Bil
VRTX
Vertex Pharmaceuticals IncFsdgxsq$108.6 Bil
REGN
Regeneron Pharmaceuticals IncJpjjkl$106.0 Bil
MRNA
Moderna IncZpq$35.2 Bil
ARGX
argenx SE ADRTqyx$23.7 Bil
BNTX
BioNTech SE ADRJtf$21.1 Bil
ALNY
Alnylam Pharmaceuticals IncNkmwl$19.0 Bil
BMRN
Biomarin Pharmaceutical IncJvsmzt$16.3 Bil
RPRX
Royalty Pharma PLC Class AKfpdyd$13.6 Bil
INCY
Incyte CorpDlynkm$13.1 Bil

Sponsor Center